ArticleFrontiers in oncology2021
Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- ZIF-8 nanoplatform coordinating ZnInternational journal of pharmaceutics: X · 2026Article
- The role of the cGAS-STING pathway in male reproductive disorders.Molecular biology reports · 2026Review
- Nanomedicine in immunotherapy of urinary system tumors: advances, synergistic strategies, and translational challenges.Journal of nanobiotechnology · 2026Review
- Targeting autophagy to enhance cancer immunotherapy: emerging mechanisms and strategies.Medical oncology (Northwood, London, England) · 2025Review
- Nanodelivery Strategies for STING Agonists: Toward Efficient Cancer Immunotherapy.International journal of nanomedicine · 2025Review
- Article
- The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.Cellular & molecular biology letters · 2024Review
- Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer.Medical oncology (Northwood, London, England) · 2024Article
- Activation of Stimulator of Interferon Genes (STING): Promising Strategy to Overcome Immune Resistance in Prostate Cancer.Current medicinal chemistry · 2024Review
- STING activation increases the efficiency of temozolomide in PTEN harbouring glioblastoma cells.Turkish journal of medical sciences · 2024Article
- Targeting STING signaling for the optimal cancer immunotherapy.Frontiers in immunology · 2024Review
- Unraveling the cGAS/STING signaling mechanism: impact on glycerolipid metabolism and diseases.Frontiers in medicine · 2024Review
- Activation of STING in Response to Partial-Tumor Radiation Exposure.International journal of radiation oncology, biology, physics · 2023Article
- The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.Current oncology reports · 2023Review
- Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.Frontiers in immunology · 2023Article
- Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy.Trends in immunology · 2022Review
- STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells.Oncoimmunology · 2022Article
- Immune Inflammation Pathways as Therapeutic Targets to Reduce Lethal Prostate Cancer in African American Men.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the second most commonly diagnosed cancer in men with mortality rates, overtaking those for breast cancer in the last 2 years in the UK. Despite advances in prostate cancer treatments, over 25% of men do not survive over 5 years with advanced disease. Due to the success of immunotherapies in treating other cancers, this treatment modality has been investigated for Prostate cancer, however, the sole FDA approved immunotherapy so far (Provenge™) only extends life by a few months. Therefore, finding immunotherapeutic agents to treat prostate cancer is of major interest. Our group has previously shown that Interleukin-15 (IL-15), unlike other therapeutic cytokines such as IL-2 and IL-12, can stimulate expansion and activity of CD8 T cells and NK cells
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.